Business · 20/09/2006Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for MYCAMINE Patent Extension
Summary
The US Food and Drug Administration (FDA) has officially confirmed the review period for MYCAMINE's patent extension application, following a submission to the Department of Commerce's Director of Patents and Trademarks.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →